4597 — Solasia Pharma KK Share Price
0.000.00%
Last trade - 00:00- ¥8bn
- ¥7bn
- ¥617m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.92 | ||
| Price to Tang. Book | 6.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.14% | ||
| Return on Equity | -55.62% | ||
| Operating Margin | -294.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 1,310 | 454 | 559 | 1,092 | 617 | 1,360 | 2,044 | 14.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Solasia Pharma KK is a Japan-based company with a product development pipeline of pharmaceuticals and medical devices, and is engaged in the development and sale of pharmaceuticals. Its main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events caused by the administration of malignant tumor treatment drugs and radiation therapy, and improve the treatment of malignant tumors and the quality of life (QOL) of patients. It is engaged in in-licensing of rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates. Its development pipeline includes the transdermal granisetron preparation Sancuso, the organic arsenic preparation darinaparsin, the oral wound dressing protective material episil, and the intracellular superoxide remover PledOx.
Directors
- Yoshihiro Arai PRE (47)
- Toshio Miyashita CFO (53)
- Norikazu Eiki IND (73)
- Stanley Lau IND (67)
- Jiro Mizukawa IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 22nd, 2007
- Public Since
- March 24th, 2017
- No. of Shareholders
- 30,839
- No. of Employees
- 24
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 197,129,800
- Address
- 3F, Shiodome Bldg., 1-2-20, Kaigan, MINATO-KU, 105-0011
- Web
- https://solasia.co.jp/
- Phone
- +81 358438045
- Auditors
- BDO Sanyu & Co.
Upcoming Events for 4597
Q2 2024 Solasia Pharma KK Earnings Release
Similar to 4597
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Solasia Pharma KK share price?
As of Today at 11:24 UTC, shares in Solasia Pharma KK are trading at ¥27. This share price information is delayed by 15 minutes.
How has the Solasia Pharma KK share price performed this year?
Shares in Solasia Pharma KK last closed at ¥27 and the price had moved by -43.75% over the past 365 days. In terms of relative price strength the Solasia Pharma KK share price has underperformed the Nikkei 225 Index by -52.6% over the past year.
What are the analyst and broker recommendations for Solasia Pharma KK?
The overall consensus recommendation for Solasia Pharma KK is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Solasia Pharma KK dividend yield?
Solasia Pharma KK does not currently pay a dividend.
Does Solasia Pharma KK pay a dividend?
Solasia Pharma KK does not currently pay a dividend.
When does Solasia Pharma KK next pay dividends?
Solasia Pharma KK does not currently pay a dividend.
How do I buy Solasia Pharma KK shares?
To buy shares in Solasia Pharma KK you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Solasia Pharma KK?
As of the previous close price of ¥27, shares in Solasia Pharma KK had a market capitalisation of ¥5bn.
Where are Solasia Pharma KK shares listed?
Here are the trading details for Solasia Pharma KK:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4597
What kind of share is Solasia Pharma KK?
Based on an overall assessment of its quality, value and momentum Solasia Pharma KK is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Solasia Pharma KK share price forecast for 2024?
The analyst consensus target price for shares in Solasia Pharma KK is ¥54. That is 100% above the last closing price of ¥27.
Analysts covering Solasia Pharma KK currently have a consensus Earnings Per Share (EPS) forecast of -¥4 for the next financial year.
What is the trend in the Solasia Pharma KK share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Solasia Pharma KK. Over the past six months, its share price has underperformed the Nikkei 225 Index by -53.13%.
As of the last closing price of ¥27, shares in Solasia Pharma KK were trading -30.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Solasia Pharma KK PE Ratio?
The Solasia Pharma KK PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Solasia Pharma KK?
Solasia Pharma KK's management team is headed by:
- Yoshihiro Arai - PRE
- Toshio Miyashita - CFO
- Norikazu Eiki - IND
- Stanley Lau - IND
- Jiro Mizukawa - IND